4 documents found, page 1 of 1
Gender, body mass index and rheumatoid arthritis disease activity: Results from...
Jawaheer, Damini; Olsen, Jørn; Lahiff, Maureen; Forsberg, Sinikka; Lähteenmäki, Jukka; da Silveira, Ines Guimaraes; Rocha, Francisco AirtonMade available in DSpace on 2022-04-28T18:56:40Z (GMT). No. of bitstreams: 0 Previous issue date: 2010-12-01; Objective: To investigate whether body mass index (BMI), as a proxy for body fat, influences rheumatoid arthritis (RA) disease activity in a gender-specific manner. Methods: Consecutive patients with RA were enrolled from 25 countries into the QUEST-RA program between 2005 and 2008. Clinical and demogra...
Effectiveness and treatment retention of TNF inhibitors when used as monotherap...
Lindström, Ulf; Di Giuseppe, Daniela; Delcoigne, Bénédicte; Glintborg, Bente; Möller, Burkhard; Ciurea, Adrian; Pombo-Suarez, ManuelBackground: Comedication with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) during treatment with tumour necrosis factor inhibitors (TNFi) is extensively used in psoriatic arthritis (PsA), although the additive benefit remains unclear. We aimed to compare treatment outcomes in patients with PsA treated with TNFi and csDMARD comedication versus TNFi monotherapy. Methods: Patients with P...
Impact of discordance between patient’s and evaluator’s global assessment on tr...
Michelsen, Brigitte; Ørnbjerg, Lykke Midtbøll; Kvien, Tore K.; Pavelka, Karel; Nissen, Michael J.; Nordström, Dan; Santos, Maria; Koca, Suleyman SerdarObjectives: To assess the impact of 'patient's minus evaluator's global assessment of disease activity' (ΔPEG) at treatment initiation on retention and remission rates of TNF inhibitors (TNFi) in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) patients across Europe. Methods: Real-life data from PsA and axSpA patients starting their first TNFi from 11 countries in the European Spondyloarthritis Re...
Drug retention, inactive disease and response rates in 1860 patients with axial...
Michelsen, Brigitte; Lindström, Ulf; Codreanu, Catalin; Ciurea, Adrian; Zavada, Jakub; Loft, Anne Gitte; Pombo-Suarez, Manuel; Onen, FatosObjectives: To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) time since diagnosis and (3) different European registries. Methods: Real-life data from 13 European registries participating in the European Spondyloarthritis R...